Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 3
2023 3
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean moshkin m (107 results)?
Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
van 't Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, Fellah A, Kolijn PM, Langerak AW, Moskie M, van der Oost E, Rozendaal NEM, Baart SJ, Aerts JGJV, van Eijck CHJ. van 't Land FR, et al. Among authors: moskie m. J Clin Oncol. 2024 Sep 10;42(26):3083-3093. doi: 10.1200/JCO.23.02585. Epub 2024 Jul 1. J Clin Oncol. 2024. PMID: 38950309 Free PMC article. Clinical Trial.
Making care fit manifesto.
Kunneman M, Griffioen IPM, Labrie NHM, Kristiansen M, Montori VM, van Beusekom MM; Making Care Fit Working Group. Kunneman M, et al. BMJ Evid Based Med. 2023 Feb;28(1):5-6. doi: 10.1136/bmjebm-2021-111871. Epub 2021 Nov 23. BMJ Evid Based Med. 2023. PMID: 34815303 Free PMC article. No abstract available.
Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial.
van 't Land FR, Latifi D, Moskie M, Homs MYV, Bosscha K, Bonsing BA, Mieog SD, van der Harst E, Coene PLO, Wijsman JH, van der Schelling GP, Groot Koerkamp B, Nuyttens JJ, van Eijck CHJ; South West Pancreatic Cancer Care SWPCC consortium. van 't Land FR, et al. Among authors: moskie m. Radiother Oncol. 2023 Jun;183:109541. doi: 10.1016/j.radonc.2023.109541. Epub 2023 Feb 20. Radiother Oncol. 2023. PMID: 36813171 Clinical Trial.
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.
Kucukcelebi S, van 't Land FR, van der Burg SH, Eskens FALM, Homs MYV, Willemsen M, Onrust-van Schoonhoven A, Rozendaal NEM, Fellah A, Vadgama D, Moskie M, Bezemer K, Doukas M, van Eijck CWF, Stadhouders R, de Vos-Geelen J, van Diepen AE, Enninga I, Meijer R, Ambarkhane SV, Ellmark P, Aerts JGJV, Groeneveldt C, van Eijck CHJ. Kucukcelebi S, et al. Among authors: moskie m. Nat Commun. 2025 Nov 28;16(1):10609. doi: 10.1038/s41467-025-66092-1. Nat Commun. 2025. PMID: 41315287 Free PMC article. Clinical Trial.
Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program.
El Haddaoui H, Brood R, Latifi D, Oostvogels AA, Klaver Y, Moskie M, Mustafa DA, Debets R, van Eijck CHJ. El Haddaoui H, et al. Among authors: moskie m. Cancers (Basel). 2022 Mar 8;14(6):1377. doi: 10.3390/cancers14061377. Cancers (Basel). 2022. PMID: 35326528 Free PMC article.